Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-week open-label study of omalizumab in Japanese children with inadequately controlled allergic asthma
jRCT2080221137Phase 3
- Sponsor
- Novartis
- Start
- Jun 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of omalizumab in allergic asthma, sponsored by Novartis. Primary endpoints: Pharmacokinetics of omalizumab, Pharmacodynamics of omalizumab and 2 more.
02
Drugs
omalizumab
03
Conditions
allergic asthma
Beyond the preview
Go deeper on jRCT2080221137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221137.